Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy

Albert Grinshpun*, Nancy Gavert, Roy Zvi Granit, Hadas Masuri, Ittai Ben-Porath, Shani Breuer, Aviad Zick, Shai Rosenberg, Myriam Maoz, Avital Granit, Eli Pikarsky, Ravid Strausmman, Tamar Peretz, Amir Sonnenblick

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The growing use of genomic testing presents new treatment options but also new dilemmas. We describe here a heavily-pretreated metastatic triple negative breast cancer patient who failed to respond to conventional treatment. Genomic analyses were performed that discovered several targetable alterations (e.g. FGFR1, CDK6, INSR) and created a clinical challenge–which target to target first? Our solution to this relatively common scenario was using ex-vivo organ culture (EVOC) system to prioritize treatment directed toward the best molecular target. EVOC enabled the trial of several potent targeted agents (Everolimus, Linsitinib, Palbociclib, AZD4547) and allowed semi-quantitative measurement of tumor response. The best response was to FGFR inhibitor, AZD4547. Consequently, the most accessible FGFR inhibiting agents (Pazopanib, then Nintedanib) were administered and some response was achieved. This report provides a potential rationale for utilizing EVOC system to predict tumor response to targeted therapy when multiple targets are proposed.

Original languageAmerican English
Pages (from-to)645-648
Number of pages4
JournalCancer Biology and Therapy
Issue number8
StatePublished - 2018

Bibliographical note

Publisher Copyright:
© 2018, © 2018 Taylor & Francis Group, LLC.


  • Breast Cancer
  • Ex-vivo
  • Patient Derived Xenografts
  • Targeted Therapy
  • Triple Negative


Dive into the research topics of 'Ev vivo organ culture as potential prioritization tool for breast cancer targeted therapy'. Together they form a unique fingerprint.

Cite this